Inhomogeneous dose escalation for NSCLC: Full dosimetric analysis of the phase III NARLAL2 trial

被引：0
|
作者：
Lutz, Christina M. [1 ]
Nielsen, Tine B. [2 ]
Lund, Mikkel D. [3 ]
Schytte, Tine [2 ]
Hansen, Torben S. [3 ]
Hoffmann, Lone [1 ,4 ]
Ottosson, Katarina W. [5 ]
Peucelle, Cecile [6 ]
Rusten, Espen [7 ]
Levin, Nina [8 ]
Brink, Carsten [2 ]
Gronberg, Bjorn H. [8 ,9 ]
Haakensen, Vilde D. [7 ]
Hansen, Olfred [2 ]
Khalil, Azza A. [1 ,4 ]
Knap, Marianne M. [1 ]
Kristiansen, Charlotte [3 ]
Nielsen, Morten [2 ]
Persson, Gitte F. [5 ,10 ]
Pohl, Mette [6 ]
Thing, Rune S. [3 ]
Moller, Ditte S. [1 ,4 ]
机构：
[1] Aarhus Univ Hosp, Dept Oncol, Aarhus, Denmark
[2] Odense Univ Hosp, Dept Oncol, Odense, Denmark
[3] Univ Hosp Southern Denmark, Vejle Hosp, Dept Oncol, Vejle, Denmark
[4] Aarhus Univ, Dept Clin Med, Aarhus, Denmark
[5] Copenhagen Univ Hosp Herlev & Gentofte, Dept Oncol, Herlev, Denmark
[6] Rigshosp, Dept Oncol, Copenhagen, Denmark
[7] Oslo Univ Hosp, Dept Oncol, Oslo, Norway
[8] St Olavs Hosp, Dept Oncol, Trondheim, Norway
[9] Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Trondheim, Norway
[10] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
来源：
RADIOTHERAPY AND ONCOLOGY | 2024年 / 194卷
关键词：
NSCLC; dose escalation;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2381
引用
收藏
页码：S1736 / S1739
页数：5
相关论文
共 50 条
  • [31] Adaptive Dose Painting vs standard IMRT in a randomized phase II trial: a dosimetric analysis.
    Vercauteren, T.
    De Bruycker, A.
    Duprez, F.
    Daisne, J.
    Olteanu, A. M. L.
    Deheneffe, S.
    Berwouts, D.
    De Neve, W.
    Madani, I.
    Paelinck, L.
    Speleers, B.
    Goethals, I.
    De Gersem, W.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S105 - S106
  • [32] INDIVIDUALIZED (CHEMO)-RADIATION DOSE ESCALATION FOR STAGE I-III NON-SMALL CELL LUNG CANCER (NSCLC) ACCORDING TO THE MEAN LUNG DOSE (MLD): A PHASE II TRIAL (NCT00573040).
    De Ruysscher, D.
    Wanders, R.
    Bootsma, G.
    Hochstenbag, M.
    Geraedts, W.
    Pitz, C.
    Simons, J.
    Bentzen, S. M.
    Lambin, P.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S38 - S39
  • [33] Design of a dose escalation phase 1/2 trial for a novel combined cell and oncolytic viral therapy
    Contag, Pamela R.
    CANCER RESEARCH, 2018, 78 (13)
  • [34] Is Efficacy Result in Phase 2 Trial Replicated in Phase 3 Trial in Advanced NSCLC: A Meta-Analysis
    Shibaki, R.
    Akamatsu, H.
    Mori, K.
    Teraoka, S.
    Kanai, K.
    Hayata, A.
    Tokudome, N.
    Akamatsu, K.
    Koh, Y.
    Ueda, H.
    Nakanishi, M.
    Yamamoto, N.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2384 - S2384
  • [35] Individualized radiation dose escalation for stage I-III non-small cell lung cancer (NSCLC) based on normal tissue constraints: mature results of a phase II trial
    van Baardwijk, Angela
    Reymen, Bart
    Wanders, Rinus
    Bootsma, Gerben
    Pitz, Cordula
    Hochstenbag, Monique
    Geraedts, Wiel
    Lunde, Ragnar
    De Ruysscher, Dirk
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S336 - S336
  • [36] TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis
    Cole, M.
    Yap, C.
    Buckley, C.
    Ng, W. F.
    McInnes, I.
    Filer, A.
    Siebert, S.
    Pratt, A.
    Isaacs, J. D.
    Stocken, D. D.
    TRIALS, 2021, 22 (01)
  • [37] TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis
    M. Cole
    C. Yap
    C. Buckley
    W. F. Ng
    I. McInnes
    A. Filer
    S. Siebert
    A. Pratt
    J. D. Isaacs
    D. D. Stocken
    Trials, 22
  • [38] Single dose high-dose-rate brachytherapy with focal dose escalation for prostate cancer: Mature results of a phase 2 clinical trial
    Armstrong, Shreya
    Brown, Stephanie
    Stancliffe, May
    Ostler, Peter
    Hughes, Robert
    Hoskin, Peter
    Alonzi, Roberto
    RADIOTHERAPY AND ONCOLOGY, 2021, 159 : 67 - 74
  • [39] Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial
    Gomez-Iturriaga, Alfonso
    Buchser, David
    Mayrata, Esther
    San Miguel, Inigo
    Gonzalez, Alba
    Suarez, Fernan
    Martinez-Indart, Lorea
    Minguez, Pablo
    Espinosa, Jose
    Perez, Fernando
    Cacicedo, Jon
    Casquero, Francisco
    RADIOTHERAPY AND ONCOLOGY, 2020, 146 : 16 - 20
  • [40] Biomarker analysis of regorafenib dose escalation study (RECC study): A phase II multicenter clinical trial in Japan
    Enomoto, M.
    Yamada, T.
    Nakamura, M.
    Ishiyama, S.
    Yokomizo, H.
    Kosugi, C.
    Sonoda, H.
    Ishibashi, K.
    Kuramochi, H.
    Nozawa, K.
    Yoshida, Y.
    Ohta, R.
    Hasegawa, S.
    Ichikawa, D.
    Hashiguchi, Y.
    Hirata, K.
    Katsumata, K.
    Ishida, H.
    Koda, K.
    Sakamoto, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S1277 - S1277
12345